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Abstract
Background: We conducted a cross-sectional integrated bio-behavioral survey among sex partners of persons who
inject drugs (PWID) to explore reasons for reported increase in reporting of heterosexually transmitted HIV in
Kazakhstan and Kyrgyzstan.
Methods: Sexual partners of PWID were recruited through PWID. Behavioral data were collected through semi-
structured interviews. Dried blood spots were obtained and tested for HIV and hepatitis C virus antibodies (HCVAb).
Descriptive univariate and bivariate analyses, and multivariate analyses using logistic regression modeling were
performed to identify factors associated with HIV and HCV infections.
Results: Among 1982 sex partners of PWID, overall HIV prevalence was 6.4%; 5.1% and 12.9% among those reported
never and ever injecting drugs, respectively (p < 0.001). Overall, HCVAb prevalence was 21.3%; 15.0% and 53.9% among
those reported never and ever injecting drugs, respectively (p < 0.001). Of HCV-positive participants, 58% and
34% (p < 0.001) reported prior history of injecting drug use among men and women, respectively. HIV
prevalence was lower among HCV-negative (4.2%) compared to HCV-positive participants (14.4%) (p < 0.001).
HIV prevalence was 3.5% (95%CI = 2.4–4.6) in a subset of female participants with no reported prior injecting
drug use history and who were HCVAb-negative and did not report having an HIV-positive sex partner.
Participant sex and number of sex partners as well as use of condoms in the past 12 months were not
associated with HIV seropositivity.
Conclusions: High prevalence of HCV among sex partners of PWID who denied ever injecting drugs suggests
underreporting of injecting practices. The increased attribution of HIV infection to sexual transmission based on self-
report may be partly explained by underreporting of injection drug use due to stigmatization of this behavior.
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Background
Central Asia remains one of the few regions in the world
where the HIV epidemic is growing [1]. While HIV
prevalence in the general population is less than 0.5%,
the prevalence is above 5% in key populations, including
persons who inject drugs (PWID) [2]. Injecting drug use
has been noted as the main driver of HIV epidemics in
the region; however, since 2010, national surveillance
data from Kazakhstan and Kyrgyzstan suggest a steady
increase in heterosexual transmission of HIV, based on
self-report by newly detected HIV-infected individuals,
especially among women [3]. In 2015, these national
data collected as part of routine HIV case surveillance
from HIV testing sites indicated that more than 50% of
persons living with HIV (PLHIV) in both Kazakhstan
and Kyrgyzstan were PWID [4] and that sex partners of
PLHIV constituted a substantial proportion of newly
detected HIV cases [3]. It is, thus, reasonable to assume
that sex partners of PLHIV who are PWID are at
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increased risk for HIV infection and may constitute a
growing percentage of newly detected HIV cases. At the
same time, according to the national HIV testing data
(also referred to as Form 4), testing yield among women
tested for HIV as part of their antenatal care from 2010
to 2015 remained stable at 0.01% in Kazakhstan and at
0.03–0.04% in Kyrgyzstan.
The reasons for the reported increase in the number
of reported cases of sexually acquired HIV infections
registered in the national surveillance systems are not
fully understood. The critical question is whether the in-
crease in reported heterosexually acquired HIV among
sexual partners of PWID who are HIV-infected is largely
due to true increases in sexual transmission or due to
underreported injection drug use by sexual partners who
are PWID. No study to date has attempted to better
understand the reasons behind the increased reporting
of heterosexually acquired HIV infection in Kazakhstan
and Kyrgyzstan.
To address this gap, we examined biological and beha-
vioral characteristics of sex partners of PWID in order to
assess possible reasons for reported increases in hetero-
sexual HIV transmission in Kazakhstan and Kyrgyzstan.
Methods
Aim and design
We conducted a cross-sectional survey in a convenience
sample of sex partners of PWID to determine HIV and
hepatitis C virus (HCV) seroprevalence and to identify
factors associated with HIV infection. Verbal informed
consent was obtained from all participants.
Setting
The data were collected during June–August 2013.
The study was conducted in four cities in Kazakhstan
(Karaganda, Temirtau, Ust-Kamenogorsk, and Kostanai) and
four cities in Kyrgyzstan (Bishkek and Tokmok, Jalalabad
and Osh) reporting the highest rates of sexually transmitted
HIV infections as per the national case surveillance data in
each of the two countries.
Study population and sampling
We enrolled consenting females or males that were at least
18 years of age who reported a history of oral, anal, or vagi-
nal sex with a PWID during the last 12months. To limit to
non-injecting persons, both people who reported injection
drug use within the preceding 12months and those who
had visible marks of recent injections were excluded. Most
participants were recruited directly through PWID, the lat-
ter via respondent-driven sampling to participate in rou-
tinely conducted national sentinel integrated biological
behavioral surveys (IBBS). As part of the routine IBBS in-
terviews, PWID were asked if they had non-injecting sex
partners during the past 12months. Following IBBS
interviews, respondents that indicated having sex partners
during the prior 12months were asked to refer their
non-injecting sex partners using recruitment coupons, de-
pending on the number of sex partners reported during the
interview. PWID participating in IBBS who brought their
sex partners to participate in the survey were compensated
with pre-paid mobile phone cards. Additional sex partners
were recruited through PWID who visited non-governmen-
tal organizations (NGOs) working with PWID rather than
during the IBBS. Sex partners of PWID who presented to
the study sites were offered participation in the study.
A total of 1640 PWID (940 in Kazakhstan and 700 in
Kyrgyzstan) included in the IBBS were approached for
recruitment of their sex partners. On average, one to
two recruitment coupons per PWID were provided (in
total 2410 coupons were distributed). A total of 2055 sex
partners of PWID presented to the study sites, and 2022
(98%) sex partners of PWID who met the selection cri-
teria agreed to participate in the study. Of 2022, 1625
(80%) were recruited through PWID in the IBBS, while
397 (20%) were recruited through PWID visiting NGOs.
Forty participants (2 in Kazakhstan and 38 in
Kyrgyzstan), whose surveys were largely incomplete,
were excluded from further analysis, thus reducing the
final number of study participants to 1982 (1125 from
Kazakhstan and 857 from Kyrgyzstan).
Serology PWID
Presence of antibodies to HIV and HCV was ascertained
by testing blood specimens collected from study partici-
pants through dried blood spot (DBS). Enzyme-linked
immunoabsorbent assay (ELISA) was used in accordance
with the national HIV (initial and confirmatory) and HCV
testing algorithms approved for use in IBBS. The types of
ELISAs used for initial testing varied by country for each
of the two viruses, but confirmatory testing was done by
Murex (ABBOTT) according to the manufacturers’ in-
structions. In Kazakhstan, samples testing positive by
CombiBest anti-HIV 1,2 assay (Vektor-Best) were con-
firmed by Murex anti-HIV assay (ABBOTT). For HCV
testing, samples that screened positive by Best anti-HCV
assay (Vektor-Best) were confirmed by Murex anti-HCV
ELISA (ABBOTT). In Kyrgyzstan, samples testing positive
for HIV using the UniBest anti-HIV 1,2 assay (Vektor-B-
est) were confirmed by Murex anti-HIV assay (ABBOTT).
For HCV testing, samples testing positive for HCV by
RecombiBest anti-HCV-strip assay (Vektor-Best) were
confirmed by Murex anti-HCV ELISA (ABBOTT).
Sample size and statistical analysis
The target sample size was determined based on the
average number of non-injecting sex partners per PWID
per year as reported in the IBBS among PWID.
Deryabina et al. Harm Reduction Journal            (2019) 16:1 Page 2 of 6
Following descriptive univariate and bivariate analyses,
multivariate analyses were conducted using logistic re-
gression modeling to identify factors independently asso-
ciated with HIV and HCV, while adjusting for potential
clustering in participants and their recruiter by using
generalized estimating equations (GEE).
To estimate HIV prevalence among a subset of partici-
pants least likely to be injecting drugs, we conducted a
sub-analysis among sex partners who reported no prior
injecting use history and tested negative for HCVAb.
All analyses were conducted using Stata [5]. Pearson’s
chi-square test was used to look at the magnitude of dif-
ferences and judge the significance. Associations were
assessed to be significant if p values were < 0.05. Full
models (containing all the covariates) were tested for
model fit using the Pearson’s goodness of fit test before
model reduction for assessing independent associations.
Results
Social and demographic characteristics
Participants included 1706 women (86%) and 276 men
(14%) ranging in age from 18 to 65 years with a median
and mean age of 33 years (IQR = 27–39). Most male par-
ticipants either had a cohabiting partner without being
officially married (33%) or were single and not residing
with a partner (31%), while female participants were ei-
ther married (22%), had a cohabiting partner without be-
ing married (25%), were single and not residing with a
partner (24%), or were divorced (22%). Responses to
levels of income and contributions to family budgets also
varied by sex with 43% of male participants responding
that they were key income generators for their families,
while only 24% of women gave this response (p < 0.001).
Prior drug injecting behavior
By definition, all participants reported not having injected
drugs in the 12months preceding study entry. Among the
latter group, most participants (83.6%; 95%CI 81.9–85.2)
reported never injecting drugs. Reports of ever injecting
drugs were significantly higher among male partners
(38.8%; 95%CI 33.0–44.6) compared to female partners
(12.8%; 95%CI 11.2–14.4) (p < 0.001).
Sexual behavior and history of sexually transmitted
infections
Regarding the number of sex partners over the past 12
months, the majority of men (201 participants, 72.8%)
reported more than one partner, while 42.1% women
(718 participants) did so (p < 0.001). The majority (836
participants, 91.0%) of participants with more than one
sex partner in the last 12 months reported having had
sex with both PWID and with individuals who did not
inject drugs. Of all participants, in the past 12 months,
30.0% (95%CI 28.0–32.0) reported that they always used
condoms with their partners who inject drugs and 28.1%
(95%CI 25.0–31.0) of those who had both PWID and
non-injecting sex partners reported always using
condoms with non-injecting partners (p > 0.05). Use of
condoms with different types of partners did not differ
by sex (p > 0.05) (Table 1).
Reports of symptoms of sexually transmitted infections
(STIs) in the past 6 months were significantly higher
among female participants (23.4%; 95%CI 21.4–25.4)
compared to male participants (9.8%; 95%CI 6.2–13.3)
(p < 0.001). Frequency of condom use was not associated
with report of STI symptoms. However, women who re-
ported more than one sex partner over the past 12
months and had history of ever injecting drug use in the
past, i.e., prior to the last 12 months, were more likely to
report STI symptoms in the past 6 months.
HCV prevalence
HCV seroprevalence among participants was high (21.3%)
and significantly higher among men compared to women
(48.9% in men and 16.9% in women, (p < 0.001). Overall,
HCV seroprevalence was significantly higher among those
who reported more than one sex partner in the last 12
months (23.5% vs 19.5%, X2 (1) = 4.77, p = 0.03), and this
was noted similarly among women and men. HCV preva-
lence was significantly higher among participants who had
ever injected drugs in the past (72.9% in men and 44.5%
in women) compared to those who reported never
injecting drug use (33.7% in men and 12.8% in
women), p < 0.001). The history of ever injecting
drugs was the only significant predictor of HCVAb
positivity in men and women (OR = 6.6; 95%CI = 5.1–8.5)
(Table 2); however, only 57.8% of HCVAb-positive men
and 33.6% of HCVAb-positive women (p < 0.001) reported
prior history of ever injecting drugs. Of 245 HCVAb-posi-
tive women with HIV, 68.2% reported never injecting drug
use (95%CI 61.9–74.0).
In the subset of 1572 participants (79% of all study
participants) with no reported prior injecting drug use
history that were also HIV-negative, HCV prevalence
was 11.8% in women and 31.2% in men (p < 0.001).
HIV prevalence
Overall, HIV prevalence among participants was 6.4%
and marginally higher among men (9.1%) compared to
women (6.0%) (p = 0.05). Irrespective of sex, HIV preva-
lence was significantly lower among those who reported
no history of injecting drug use (5.1%; 95%CI 4.1–6.3)
versus those who had ever injected drugs in the past
(12.9%; 95%CI 9.5–17.1) (p < 0.001). HIV prevalence was
significantly lower (4.2%) in participants who were
HCV-negative compared to HCV-positive participants
(14.4%) (p < 0.001). There was no statistically significant
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difference in HIV prevalence by number of sex partners
in the past 12 months.
A limited number of participants (31 females and 6
males; 2% of study population) reported being aware of
having an HIV-positive partner. For female participants,
having an HIV-positive partner and their own prior use of
injecting drugs were two factors associated with signifi-
cantly higher HIV-positive prevalence (p < 0.001), but the
number of sex partners (p = 0.37), reported STI symptoms
(p = 0.05), and the reported consistent use of condoms
with all partners over the past 12months (p = 0.53) were
not associated with seropositivity. For male participants,
having an HIV-positive partner and the reported consist-
ent use of condoms with all partners over the past 12
months were the only factors associated with higher risk
of HIV seropositivity (p < 0.001).
In the subset of 1103 female participants (56% of all
study participants; 65% of all female participants) with
no reported prior injecting drug use history that were
also HCV-negative and did not report having an
HIV-positive sex partner, HIV prevalence was 3.5%
(95%CI = 2.4–4.6). In the final logistic regression model,
the number of sex partners, reporting consistent use of
condoms and having STI symptoms, was not signifi-
cantly associated with HIV seropositivity.
Discussion
This study demonstrated that both HIV and HCV preva-
lence among female sex partners of PWID was significantly
higher than that estimated in the general population of
women and other populations, like blood donors (less than
0.5% for HIV and less than 5% for HCV), in Kazakhstan
and Kyrgyzstan [6–9]. Among female sex partners, reported
history of prior injection drug use and of having an
HIV-positive sex partner who injects drugs was associated
with HIV infection. Among male participants, reported
consistent use of condoms was associated with HIV sero-
positivity; however, this may be due to the fact that men
who are aware of their HIV-positive status or the
HIV-positive status of their partner were more likely to use
condoms as shown by several other studies [10–12].
The study identified, unsurprisingly, that having an
HIV-positive male sex partner who injects drugs was asso-
ciated with HIV infection among female participants who
had no history of drug injection. In addition, as PWID in
Kazakhstan and Kyrgyzstan account for the largest
proportion (more than 50%) of all confirmed HIV cases,
having sex with a PWID presents a substantial risk for
sexual transmission of HIV. Alarmingly, less than one
third of women participants in our study reported consis-
tent use of condoms with their PWID partners over the
past 12months. This finding is similar to the results
reported from other studies [13–15]. It is likely that the
sexual transmission from HIV-positive PWID to their sex
partners is facilitated by the fact that the majority of
PWID who are HIV-positive are likely unaware of their
HIV-positive status and, if aware, are unlikely to be en-
rolled in care or have initiated antiretroviral therapy or
achieved viral suppression [16], consequently enhancing
the risk of HIV transmission [17].
An intriguing finding from our study is the high HIV
prevalence (4.4%) among sex partners of PWID who
Table 1 Selected sexual behaviors reported in the preceding 12 months
Men (N = 276) % (95% confidence interval) Women (N = 1706) % (95% confidence interval) p-value
Reported more than one sex partner 72.8% (67.5–78.1) 42.1% (39.7–44.4) < 0.001
Use of condoms with PWID partners
Always 32.6% (27.1–34.5) 29.5% (27.4–31.8) 0.30
Sometimes 38.8% (33.0–44.8) 43.1% (40.8–45.5) 0.30
Never 28.6% (23.4–34.3) 27.3% (25.2–29.5) 0.65
Use of condoms with non-PWID partners among respondents who reported having sex with both PWID and non-PWID partners in the preceding
12 months (N = 196 men and 650 women)
Always 30.6% (24.2–37.6) 27.2% (23.8–30.8) 0.36
Sometimes 41.3% (34.4–48.6) 52.3% (48.4–56.2) 0.36
Never 28.1% (21.9–34.9) 20.5% (17.4–23.8) 0.35
Table 2 Factors and their association with HCV seropositivity among participants based on multivariate analyses (N = 1982)
Adjusted odds ratio (aOR) p-value 95% confidence interval
History of ever injecting drug use in the past 5.41 < 0.001 4.14 7.05
Male gender 3.48 < 0.001 2.58 4.70
More than one sex partner in the past 12 months 0.95 0.68 0.75 1.21
Reported always using condoms during the past 12 months 0.90 0.49 0.68 1.20
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reported never injecting drugs and who did not report
having an HIV-positive PWID sex partner. This finding
is consistent with results from another study conducted
among sex partners of PWID in Almaty, Kazakhstan,
which showed 10.4% HIV prevalence among female
partners who reported never injecting drugs and the
authors in the latter study assumed that HIV infection
in this group occurred heterosexually [18]. In our study,
HCV seroprevalence in the subset of sex partners of
PWID who reported never injecting drugs and who did
not report having an HIV-positive PWID sex partner
was also high (13%). HCV is very effectively transmitted
by injections and has been used as a biomarker for
injecting-related risks [19, 20]. Sexual transmission of
HCV does occur, although rarely, among HIV-infected
women and HIV-infected MSM [21, 22]. In other popu-
lations, sexual transmission of HCV in heterosexual
couples is unlikely [23–25], and therefore, HCV infec-
tion can serve as a marker of parenteral transmission.
This marker may be quite useful as earlier studies
showed that self-reported information about injection
drug use can be unreliable, usually underestimating such
behavior, especially among women who often avoid dis-
closing their drug injection history due to fear of stigma
[26]. Thus, it is interesting to note that only a third of
all HCV-positive women and almost 70% of all
HCV-positive women without HIV infection in our
study reported no prior history of injecting drug use,
suggesting possible underreporting of injecting behavior.
The absence of significant changes in the rates of HIV
prevalence among pregnant women in both countries
rules out increased antenatal screening as a cause of in-
creased reporting of heterosexually acquired HIV, thus
supporting the possibility that the reported increased
prevalence of heterosexual transmission may be due to
underreporting of injecting behavior.
The study had several limitations. It was conducted in
select cities in Kazakhstan and Kyrgyzstan, which have
the highest reported rates of HIV transmitted through
sex; therefore, the survey results cannot be fully extrapo-
lated to all regions or to Kazakhstan and/or Kyrgyzstan.
In addition, the sampling of sex partners was not ran-
dom, which may have influenced the prevalence of HIV
and HCVAb. Additionally, ascertainment of drug use
was dependent on self-report and examination for
evidence of active drug use such as signs of intoxication
or fresh injection marks does not exclude history of in-
jection drug use. Lastly in our study, for prior sex beha-
viors, participants were asked to report on the number
of sex partners during the past 12 months, which differs
from the usual recall period used in studies of sex be-
havior. A meta-analysis that included 28 studies [27]
showed that a recall period of 6 months was best for
recalling a number of sex partners.
Conclusion
HIV and HCV prevalence were alarmingly high among
reportedly non-injecting sex partners of PWID in
Kazakhstan and Kyrgyzstan. The high prevalence of
HCV suggests possible underreporting of previous or
current injection drug use, especially among women,
likely due to fear of stigma and the need to provide so-
cially desirable responses to questions regarding route of
HIV acquisition. The study is unable to determine the
magnitude of the effect of underreporting of injecting
behaviors on the number of HIV-positive individuals
who report sexual transmission as their risk factor for
HIV acquisition. More accurate data on risk behavior for
HIV acquisition will require training of surveillance offi-
cers in how to gain the confidence of the respondents,
assuring them confidentiality of all reported information
and the inclusion of HCVAb testing among individuals
identified with HIV infection.
Programs for the prevention of HIV are urgently
needed for PWID and their sex partners. Such programs
should address both safer injecting drug use and safer
sex behaviors in both groups. Establishing and scale-up
of accessible programs for HIV testing and counseling,
including rapid HIV testing, linkage of those found to be
HIV-positive to care with prompt initiation of antiretro-
viral therapy are urgently needed, especially among those
in discordant partnerships, with focus on achieving and
maintaining viral suppression. In addition, scale-up of
harm reduction programs including opioid agonist ther-
apy is critical to reduce HIV transmission and improve
engagement and adherence with HIV prevention and
treatment which is of paramount importance to control
the HIV epidemic in this region of the world.
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